Find the right fit for you - faster
Get tailored insights about working at Lev Pharmaceuticals in one quick step.
Lev Pharmaceuticals Snapshot
Lev Pharmaceuticals wants be a healer for a wide variety of patients. The company is developing a series of drugs to fight inflammatory ailments. Its treatment for angioedema (a skin swelling disorder), Cinryze, has received FDA approval as well as orphan drug status, which gives the company exclusive rights to market the drug for seven years. Lev Pharmaceuticals' research also extends to combating heart attack, Alzheimer's, and bowel disease. The company's development candidates are based on inhibitor protein C1-INH. Lev Pharmaceuticals has been acquired by fellow biotech company ViroPharma.
